loading page

REAL-WORLD CLINICAL OUTCOMES ASSOCIATED WITH CANAGLIFLOZIN IN PATIENTS AGED 65 YEARS AND OLDER WITH TYPE 2 DIABETES MELLITUS IN SPAIN: THE OLD REAL-WECAN STUDY.
  • +3
  • MANUEL GARGALLO-FERNANDEZ,
  • Alba Galdón Sanz-Pastor ,
  • Teresa Antón-Bravo ,
  • MIGUEL BRITO-SANFIEL,
  • Jaime Wong-Cruz ,
  • JUAN JOSE GORGOJO-MARTINEZ
MANUEL GARGALLO-FERNANDEZ
Hospital Infanta Leonor
Author Profile
Alba Galdón Sanz-Pastor
Fundacion Jimenez Diaz-UTE
Author Profile
Teresa Antón-Bravo
Hospital Universitario de Móstoles
Author Profile
MIGUEL BRITO-SANFIEL
Hospital Universitario Puerta del Hierro Majadahonda
Author Profile
Jaime Wong-Cruz
Hospital Universitario Fundacion Alcorcon
Author Profile
JUAN JOSE GORGOJO-MARTINEZ
Hospital Universitario Fundacion Alcorcon
Author Profile

Abstract

Abstract Objectives The observational REAL WECAN study showed that canagliflozin 100 mg (CANA100) as add-on therapy, and canagliflozin 300 mg (CANA300), switching from prior SGLT-2i therapy, significantly improved several cardiometabolic parameters in patients with T2DM. The aim of this sub-analysis was to assess the effectiveness and safety of canagliflozin in patients aged >65 years. The primary outcome of the study was the mean change in HbA1c over the follow-up time. Materials and Methods 583 patients met the inclusion criteria (39.5% > 65 years), 279 in the CANA100 cohort (36.9 % > 65 years, mean HbA1c 8.05%) and 304 in the CANA300 cohort (41.8 % > 65 years, mean HbA1c 7.51%). Results In the CANA100 cohort, older patients showed significant reductions in HbA1c (-0.78%) and weight (-4.5 kg). Patients aged >65 years switching to CANA300 experienced a significant decrease in HbA1c (-0.27%) and weight (-2.1 kg). There were no significant differences in HbA1c and weight reductions when the cohorts of patients <65 and >65 years were compared in a multiple linear regression model. The safety profile of canagliflozin was similar in both age groups. Conclusion These findings support canagliflozin as an effective therapeutic option for older adults with T2DM